For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

Enanta Pharmaceuticals, Inc.

USPTO Granted Patents = 292

CIPO Patents = 6

EPO Patents = 25

Trademarks = 4

Forward Citations = 1,792

Loading Chart...

Loading Chart...

120 inventors (with patents filed for the assignee):

Yat Sun Or (289 out of 342 patents)

Guoqiang Wang (104 out of 108 patents)

Yao-Ling Qiu (75 out of 75 patents)

4. Xiaowen Peng (62 out of 62 patents)

5. Zhe Wang (60 out of 74 patents)

6. Ruichao Shen (49 out of 51 patents)

7. Xuechao Xing (47 out of 51 patents)

8. Jiang Long (47 out of 48 patents)

9. In Jong Kim (42 out of 43 patents)

10. Hui Cao (42 out of 46 patents)

11. Xuri Gao (41 out of 41 patents)

12. Ly Tam Phan (40 out of 46 patents)

13. Jing He (36 out of 37 patents)

14. Joseph D Panarese (32 out of 33 patents)

15. Yong He (31 out of 32 patents)

Core Competencies:

Spiropyrrolidine Derived Antiviral Agents

Tetrazole Inhibitors

Apoptosis Signal-Regulating Kinase 1

Macrocyclic Antiviral Agents

Benzodiazepine Derivatives

Heterocyclic Antiviral Compounds

Hepatitis B Antiviral Agents

Bile Acid Derivatives

Functionalized Heterocycles

RSV Inhibitors

Alkyne-Containing Antiviral Agents

Substituted Pyridines

292 patents: Sort by Forward Citations

1. 12509470 - Antiviral heterocyclic compounds (2025-12-30),

2. 12496282 - Hepatitis B antiviral agents (2025-12-16),

3. 12479854 - Spiropyrrolidine derived antiviral agents (2025-11-25),

4. 12459923 - Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof (2025-11-04),

5. 12398147 - Macrocyclic spiropyrrolidine derived antiviral agents (2025-08-26),

6. 12384753 - 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof (2025-08-12),

7. 12358921 - Antiviral heterocyclic compounds (2025-07-15),

8. 12297209 - Benzodiazepine derivatives as RSV inhibitors (2025-05-13),

9. 12281140 - Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof (2025-04-21),

10. 12268694 - Combination pharmaceutical agents as RSV inhibitors (2025-04-08),

11. 12264159 - Functionalized heterocycles as antiviral agents (2025-04-01),

12. 12162857 - Antiviral compounds (2024-12-10),

13. 12145942 - Spiropyrrolidine derived antiviral agents (2024-11-19),

14. 12145941 - Heterocyclic antiviral agents (2024-11-19),

15. 12054493 - Hepatitis B antiviral agents (2024-08-06),

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. With its proprietary chemistry technology, Enanta designs and develops novel drugs that target specific disease mechanisms. The company's main areas of focus include hepatitis B virus (HBV), respiratory syncytial virus (RSV), and non-alcoholic steatohepatitis (NASH). Enanta Pharmaceuticals is committed to improving patient lives through the delivery of innovative therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

292 Patents

#2 in Watertown, MA

#89 in Massachusetts

#1,442 in US

#2,961 in the World

Watertown, MA, United States of America

Enanta Pharmaceuticals, Inc.

Forward Citations = 1,792

120 inventors:

Yat Sun Or (289 out of 342 patents)

Guoqiang Wang (104 out of 108 patents)

Yao-Ling Qiu (75 out of 75 patents)

4. Xiaowen Peng (62 out of 62 patents)

5. Zhe Wang (60 out of 74 patents)

Please report any incorrect information to support@idiyas.com

Loading…